METHOD
Data were collected from persons that were referred because they were considered at increased risk of reacting adversely to the COVID-19 vaccine to the allergy departments in 5 referral hospitals between January 2021 and September 2022 .
Adverse reactions on a previous COVID-19 vaccination were rated into two categories: Moderate to severe manifested with generalized urticaria/erythema , observed angioedema , hypotension or stridor/decrease of oxygen saturation. Mild reactions manifested with subjective or mild objective symptoms without any of the aforementioned symptoms.
In cases, in which the allergist deemed an allergic cause of the reaction possible, skin test were performed with the Covid-19 vaccine and the excipients PEG and Polysorbate 80.
The study was approved by the Medical Ethical Committee of the UMCG and the participating centers (METC number COVID19 vaccine hypersensitivity: 202100445) and written informed consent was waived. Statistical analyses were performed using SPSS, version 27.